JP2024539922A5 - - Google Patents

Info

Publication number
JP2024539922A5
JP2024539922A5 JP2024523981A JP2024523981A JP2024539922A5 JP 2024539922 A5 JP2024539922 A5 JP 2024539922A5 JP 2024523981 A JP2024523981 A JP 2024523981A JP 2024523981 A JP2024523981 A JP 2024523981A JP 2024539922 A5 JP2024539922 A5 JP 2024539922A5
Authority
JP
Japan
Prior art keywords
alternatively
alkyl
pharmaceutically acceptable
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/128251 external-priority patent/WO2023072248A1/zh
Publication of JP2024539922A publication Critical patent/JP2024539922A/ja
Publication of JP2024539922A5 publication Critical patent/JP2024539922A5/ja
Pending legal-status Critical Current

Links

JP2024523981A 2021-10-29 2022-10-28 ピリジル含有化合物 Pending JP2024539922A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202111269381.X 2021-10-29
CN202111269381 2021-10-29
CN202210233624.2 2022-03-10
CN202210233624 2022-03-10
CN202210849103.X 2022-07-19
CN202210849103 2022-07-19
CN202211274771.0 2022-10-18
CN202211274771 2022-10-18
PCT/CN2022/128251 WO2023072248A1 (zh) 2021-10-29 2022-10-28 含吡啶基的化合物

Publications (2)

Publication Number Publication Date
JP2024539922A JP2024539922A (ja) 2024-10-31
JP2024539922A5 true JP2024539922A5 (https=) 2025-10-28

Family

ID=86159245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523981A Pending JP2024539922A (ja) 2021-10-29 2022-10-28 ピリジル含有化合物

Country Status (11)

Country Link
US (1) US20250002472A1 (https=)
EP (1) EP4424676A4 (https=)
JP (1) JP2024539922A (https=)
KR (1) KR20240090588A (https=)
CN (1) CN118055924A (https=)
AU (1) AU2022376773A1 (https=)
CA (1) CA3235436A1 (https=)
IL (1) IL312179A (https=)
MX (1) MX2024004871A (https=)
TW (1) TW202321220A (https=)
WO (1) WO2023072248A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121039118A (zh) * 2023-04-28 2025-11-28 正大天晴药业集团股份有限公司 含三唑基的化合物
WO2026082075A1 (zh) * 2024-10-15 2026-04-23 杭州百诚医药科技股份有限公司 丙烯酰胺类化合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03421B (me) * 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
US10526295B2 (en) * 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
WO2021252900A1 (en) * 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
CN112538069A (zh) * 2020-11-05 2021-03-23 苏州艾和医药科技有限公司 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022535093A5 (https=)
JP2018524298A5 (https=)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2024539922A5 (https=)
JP2014511891A5 (https=)
JP2010523522A5 (https=)
JP2019521988A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2003134544A (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
JP2013010792A5 (https=)
JP2006182786A5 (https=)
JP2019505529A5 (https=)
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
JP2014528464A5 (https=)
JP2009536620A5 (https=)
JP2006524222A5 (https=)
JP2009507896A5 (https=)
JP2017531619A5 (https=)
JP2005511547A5 (https=)
JP2017525699A5 (https=)
JP2007507494A5 (https=)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2019535723A5 (https=)
JP2015172098A5 (https=)
RU2018102449A (ru) Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии